Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial

Affiliations

• ¹ St. Vincent's University Hospital and University College Dublin, Dublin, Ireland.
• ² Private practice, Toronto, Ontario, Canada.
• ³ Diabetes and Endocrinology Consultants, Morehead City, North Carolina, USA.
• ⁴ Austin Health, Heidelberg, Victoria, Australia.
• ⁵ The Australian Centre for Accelerating Diabetes Innovation, University of Melbourne, Parkville, Victoria, Australia.
• ⁶ Department of Medicine, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.
• ⁷ Boehringer Ingelheim International GmbH, Ingelheim, Germany.
• ⁸ Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
• ⁹ Boehringer Ingelheim International GmbH, Biberach, Germany.